RAPS Convergence 2024 Focus: Human in the Lead.
As if keeping track of the changing regulatory environment wasn’t enough! The past few years have presented new challenges like the rise of AI and at a time when regulatory professionals collaborate in person less often than before. At RAPS Convergence 2024, we’ll gather to share knowledge and collaborate on solutions using the best resources we have — each other. This conference is where we can cut through the noise and confusion and learn face-to-face with experts and peers.
Schedule A Meeting Now
Please share your details to schedule a meeting with MMS representatives at this event, and let’s explore a future where accuracy, innovation, and unparalleled expertise drive your success.
Suggested For You
webinar
October 22nd, 2024
Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules
perspectives
September 30th, 2024
Meet the Leaders Driving MMS’s European Growth
perspectives
September 30th, 2024
The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry
perspectives
September 24th, 2024
Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry
perspectives
September 11th, 2024
From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
perspectives
September 4th, 2024
Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders
perspectives
August 27th, 2024
Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs
regulatory intelligence
August 27th, 2024
Recent Guidance on Diversity Action Planning
regulatory intelligence
August 26th, 2024
Oncology Programs at the FDA
regulatory intelligence
August 26th, 2024
Three Key Take Reflections on the Recent Donanemab Approval
perspectives
August 20th, 2024
Clinical Study Protocols: A Comprehensive Guide to Best Practices From A Senior Medical Writer